These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 22228328)
21. Steroid hormone receptor and COX-2 expression in chordoma. Fasig JH; Dupont WD; Olson SJ; Lafleur BJ; Cates JM Am J Clin Pathol; 2007 Sep; 128(3):375-81. PubMed ID: 17709310 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas. Saad AG; Collins MH Pediatr Dev Pathol; 2005; 8(3):362-8. PubMed ID: 16010499 [TBL] [Abstract][Full Text] [Related]
23. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Yang L; Guo T; Jiang S; Yang Z Hepatogastroenterology; 2012 Sep; 59(118):1769-75. PubMed ID: 22172411 [TBL] [Abstract][Full Text] [Related]
24. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787 [TBL] [Abstract][Full Text] [Related]
25. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165 [TBL] [Abstract][Full Text] [Related]
26. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752 [TBL] [Abstract][Full Text] [Related]
27. Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. Yamada Y; Laufer I; Cox BW; Lovelock DM; Maki RG; Zatcky JM; Boland PJ; Bilsky MH Neurosurgery; 2013 Oct; 73(4):673-80; discussion 680. PubMed ID: 23842548 [TBL] [Abstract][Full Text] [Related]
28. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas. Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J J Neurosurg; 2020 Jan; 132(1):140-149. PubMed ID: 30641849 [TBL] [Abstract][Full Text] [Related]
29. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma. El-Khalawany MA; Abou-Bakr AA J Cancer Res Ther; 2013; 9(4):613-7. PubMed ID: 24518705 [TBL] [Abstract][Full Text] [Related]
30. Disease outcomes for skull base and spinal chordomas: a single center experience. Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662 [TBL] [Abstract][Full Text] [Related]
31. [Chordomas and chordoma-like neoplasms]. Gmür W; von Hochstetter AR Pathologe; 1988 Sep; 9(5):268-75. PubMed ID: 2845386 [No Abstract] [Full Text] [Related]
32. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Bendardaf R; Buhmeida A; Hilska M; Laato M; Syrjänen S; Syrjänen K; Collan Y; Pyrhönen S Cancer Invest; 2010 Jan; 28(1):38-43. PubMed ID: 20001295 [TBL] [Abstract][Full Text] [Related]
33. [Treatment results in chordomas of the saccrococcygeal area]. Knysh IT; Tolstopiatov BA Vopr Onkol; 1982; 28(6):55-9. PubMed ID: 7090298 [TBL] [Abstract][Full Text] [Related]
34. Primary chordomas of the cervical spine: a consecutive series of 14 surgically managed cases. Wang Y; Xiao J; Wu Z; Huang Q; Huang W; Zhu Q; Lin Z; Wang L J Neurosurg Spine; 2012 Oct; 17(4):292-9. PubMed ID: 22920610 [TBL] [Abstract][Full Text] [Related]
35. Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable. Moojen WA; Vleggeert-Lankamp CL; Krol AD; Dijkstra SP Spine (Phila Pa 1976); 2011 May; 36(10):E656-61. PubMed ID: 21217422 [TBL] [Abstract][Full Text] [Related]
36. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein. Ostroumov E; Hunter CJ Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584 [TBL] [Abstract][Full Text] [Related]
37. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Stacchiotti S; Casali PG; Lo Vullo S; Mariani L; Palassini E; Mercuri M; Alberghini M; Pilotti S; Zanella L; Gronchi A; Picci P Ann Surg Oncol; 2010 Jan; 17(1):211-9. PubMed ID: 19847568 [TBL] [Abstract][Full Text] [Related]
38. Chondrosarcoma of the mobile spine: a review of 21 cases treated at a single center. Schoenfeld AJ; Hornicek FJ; Pedlow FX; Kobayashi W; Raskin KA; Springfield D; DeLaney TF; Nielsen GP; Mankin HJ; Schwab JH Spine (Phila Pa 1976); 2012 Jan; 37(2):119-26. PubMed ID: 22037533 [TBL] [Abstract][Full Text] [Related]
39. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Fanelli MF; Chinen LT; Begnami MD; Costa WL; Fregnami JH; Soares FA; Montagnini AL Histopathology; 2012 Aug; 61(2):153-61. PubMed ID: 22582975 [TBL] [Abstract][Full Text] [Related]